Getinge AB

PINK:GNGBF USA Medical Devices
Market Cap
$5.37 Billion
Market Cap Rank
#3402 Global
#2243 in USA
Share Price
$21.11
Change (1 day)
+0.00%
52-Week Range
$21.11 - $21.11
All Time High
$47.99
About

Getinge AB (publ) provides products and solutions for operating rooms, intensive-care units, and sterilization departments in Sweden and internationally. The company operates through Acute Care Therapies, Life Science, and Surgical Workflows segments. It provides extracorporeal membrane oxygenation, mechanical ventilation, advanced patient monitoring, ICU infrastructure equipment, and drainage so… Read more

Getinge AB (GNGBF) - Net Assets

Latest net assets as of June 2025: $29.02 Billion USD

Based on the latest financial reports, Getinge AB (GNGBF) has net assets worth $29.02 Billion USD as of June 2025.

Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($56.37 Billion) and total liabilities ($27.35 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.

Key Net Assets Metrics

Metric Value
Current Net Assets $29.02 Billion
% of Total Assets 51.48%
Annual Growth Rate 11.29%
5-Year Change 54.57%
10-Year Change 69.5%
Growth Volatility 13.1

Getinge AB - Net Assets Trend (2002–2024)

This chart illustrates how Getinge AB's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.

Annual Net Assets for Getinge AB (2002–2024)

The table below shows the annual net assets of Getinge AB from 2002 to 2024.

Year Net Assets Change
2024-12-31 $33.21 Billion +9.23%
2023-12-31 $30.40 Billion -0.16%
2022-12-31 $30.45 Billion +20.96%
2021-12-31 $25.18 Billion +17.17%
2020-12-31 $21.49 Billion +2.45%
2019-12-31 $20.97 Billion +6.71%
2018-12-31 $19.66 Billion -0.76%
2017-12-31 $19.81 Billion -5.31%
2016-12-31 $20.92 Billion +6.75%
2015-12-31 $19.59 Billion +4.81%
2014-12-31 $18.69 Billion +12.89%
2013-12-31 $16.56 Billion +8.95%
2012-12-31 $15.20 Billion +3.85%
2011-12-31 $14.64 Billion +10.48%
2010-12-31 $13.25 Billion +5.46%
2009-12-31 $12.56 Billion +17.67%
2008-12-31 $10.68 Billion +61.20%
2007-12-31 $6.62 Billion +10.29%
2006-12-31 $6.00 Billion +11.59%
2005-12-31 $5.38 Billion +26.04%
2004-12-31 $4.27 Billion +20.94%
2003-12-31 $3.53 Billion +11.79%
2002-12-31 $3.16 Billion --

Equity Component Analysis

This analysis shows how different components contribute to Getinge AB's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have grown by 1714.2% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (December 2024)

Component Amount Percentage
Retained Earnings $20.33 Billion 61.59%
Common Stock $136.00 Million 0.41%
Other Comprehensive Income $5.75 Billion 17.43%
Other Components $6.79 Billion 20.57%
Total Equity $33.01 Billion 100.00%

Getinge AB Competitors by Market Cap

The table below lists competitors of Getinge AB ranked by their market capitalization.

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Getinge AB's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2023 to 2024, total equity changed from 30,166,000,000 to 33,005,000,000, a change of 2,839,000,000 (9.4%).
  • Net income of 1,638,000,000 contributed positively to equity growth.
  • Dividend payments of 1,227,000,000 reduced retained earnings.
  • Other comprehensive income increased equity by 2,372,000,000.

Equity Change Factors (2023 to 2024)

Factor Impact Contribution
Net Income $1.64 Billion +4.96%
Dividends Paid $1.23 Billion -3.72%
Other Comprehensive Income $2.37 Billion +7.19%
Other Changes $56.00 Million +0.17%
Total Change $- 9.41%

Book Value vs Market Value Analysis

This analysis compares Getinge AB's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 0.17x
  • The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
  • The price-to-book ratio has decreased from 1.48x to 0.17x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
2002-12-31 $14.26 $21.11 x
2003-12-31 $15.94 $21.11 x
2004-12-31 $19.06 $21.11 x
2005-12-31 $23.96 $21.11 x
2006-12-31 $27.01 $21.11 x
2007-12-31 $29.50 $21.11 x
2008-12-31 $47.63 $21.11 x
2009-12-31 $49.60 $21.11 x
2010-12-31 $52.31 $21.11 x
2011-12-31 $57.79 $21.11 x
2012-12-31 $60.01 $21.11 x
2013-12-31 $65.40 $21.11 x
2014-12-31 $72.56 $21.11 x
2015-12-31 $75.97 $21.11 x
2016-12-31 $84.82 $21.11 x
2017-12-31 $77.31 $21.11 x
2018-12-31 $70.50 $21.11 x
2019-12-31 $75.25 $21.11 x
2020-12-31 $77.19 $21.11 x
2021-12-31 $90.87 $21.11 x
2022-12-31 $110.28 $21.11 x
2023-12-31 $110.75 $21.11 x
2024-12-31 $121.18 $21.11 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Getinge AB utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): 4.96%
  • The company may be facing challenges in efficiently utilizing shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: 4.71%
  • • Asset Turnover: 0.54x
  • • Equity Multiplier: 1.94x
  • Recent ROE (4.96%) is below the historical average (13.13%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
2002 19.69% 7.20% 0.91x 3.00x $305.88 Million
2003 22.03% 8.49% 0.76x 3.41x $424.66 Million
2004 27.20% 10.54% 0.87x 2.95x $725.74 Million
2005 21.45% 9.58% 0.82x 2.74x $607.66 Million
2006 20.96% 9.65% 0.82x 2.65x $655.70 Million
2007 18.69% 7.50% 0.72x 3.48x $573.20 Million
2008 14.31% 7.91% 0.58x 3.10x $458.80 Million
2009 15.24% 8.38% 0.61x 2.99x $657.20 Million
2010 17.22% 10.27% 0.64x 2.62x $954.70 Million
2011 17.31% 11.57% 0.53x 2.84x $1.07 Billion
2012 16.62% 10.40% 0.56x 2.83x $1.00 Billion
2013 13.82% 9.04% 0.57x 2.68x $631.90 Million
2014 7.81% 5.37% 0.50x 2.88x $-401.20 Million
2015 7.24% 4.60% 0.57x 2.77x $-530.30 Million
2016 5.79% 3.99% 0.54x 2.69x $-862.80 Million
2017 7.10% 6.12% 0.53x 2.17x $-562.40 Million
2018 -5.04% -4.00% 0.56x 2.26x $-2.89 Billion
2019 5.96% 4.60% 0.59x 2.18x $-827.60 Million
2020 15.41% 10.86% 0.66x 2.14x $1.14 Billion
2021 12.00% 10.98% 0.61x 1.80x $495.10 Million
2022 8.29% 8.80% 0.54x 1.73x $-512.80 Million
2023 8.00% 7.58% 0.59x 1.78x $-604.60 Million
2024 4.96% 4.71% 0.54x 1.94x $-1.66 Billion

Industry Comparison

This section compares Getinge AB's net assets metrics with peer companies in the Medical Devices industry.

Industry Context

  • Industry: Medical Devices
  • Average net assets among peers: $694,749,556
  • Average return on equity (ROE) among peers: -25.46%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Getinge AB (GNGBF) $29.02 Billion 19.69% 0.94x $3.80 Billion
Advanced Biomedical Technologies Inc (ABMT) $-4.46 Million 0.00% 0.00x $14.18K
Abbott Laboratories (ABT) $4.82 Billion 39.04% 1.31x $191.37 Billion
Acarix AB (publ) (ACIXF) $1.93 Million -127.02% 0.21x $26.42 Million
Adagio Medical Holdings, Inc Common Stock (ADGM) $-72.62 Million 0.00% 0.00x $4.05 Million
Adm Tronics Unltd (ADMT) $-12.69K 0.00% 0.00x $3.17 Million
Aethlon Medical Inc (AEMD) $-3.07 Million 0.00% 0.00x $2.79 Million
Acutus Medical Inc (AFIB) $126.58 Million -80.56% 0.52x $732.88K
Adapthealth Corp (AHCO) $2.07 Billion 7.56% 1.54x $914.25 Million
Allied Healthcare Products Inc. (AHPIQ) $8.88 Million -33.95% 1.22x $726.24
20/20 Biolabs, Inc. Common Stock (AIDX) $3.39 Million -59.65% 0.38x $9.18 Million